@UCSD: An Alumni Publication

An Alumni Publication   Archive vol1no3 Contact
Up Front: Letters to and from the editor
Shelf Life: Books
Cliff Notes: Student life and sports
Class Notes: Alumni profiles
Looking Back: Thoughts on UCSD
Credits: Staff and Contributors
Searching for Genghis
Victims of War
Interview with the Chancellor
What's In a Name? The Long Saga of Third College
Spanish Archive
Campus Currents
Clarion Call
Plume Assignment
The Transformation of EBU1
Geckos of the Sea
Blue Whale Blues
Swedish Science Prize
The Measure of a Woman
The Mack 'N Biz
Breathe Plant, Breathe!
Hurt Locker Robots


Class Notes May 2007: Volume 4, Number 2

Cancer Self-Testing
Sergey Sikora, M.B.A. ’06

Have you founded a company? Worked at a company started by a UCSD alum? We want to know. 
Drop us a note

When he joined the Rady School of Management’s inaugural M.B.A. class in 2004, Sergey Sikora, M.B.A. ’06, already had a Ph.D. in biochemistry from UCLA, a U.S. patent for a drug target and a clear idea of what he wanted to get out of the Rady M.B.A. program. With UC San Diego’s strengths in science and technology, Sikora was confident that the school’s focus on bringing innovation to the marketplace was the perfect fit.

While at Rady, Sikora developed a novel, direct-to-consumer strategy providing diagnostic kits to detect disease. After graduation, he was hired as the vice president of business development for San Diego-based GenWay Biotech, Inc., a manufacturer and supplier of medical diagnostic kits and their key components. And in November, they launched a variation on his diagnostic kit, a direct-to- consumer, cancer-testing service.

The service, You Test You™, enables consumers to order the test online (youtestyou.com), then test for cancer through a blood sample taken at a U.S. Healthworks lab. With a 10-day total turnaround time and a cost of $150-$180, You Test You™ is a convenient and low-cost way to periodically test for indications of cancer.

According to Sikora, “You Test You™ puts health care into the hands of consumers, many of whom do not have the time or money for expensive cancer testing. It is well-known that diagnosing cancer in its early stages leads to an increased survival rate and successful treatment. We are proud to offer a test that can make a difference.”

In April, the company announced that it had started offering the tests in Greece, and that additional agreements are being developed for other European nations.

—Keri Peckham